Vaccines Europe published its first-ever Vaccines Europe Pipeline Review 2022 of its 15 member companies, with 100 vaccine candidates as of July 2022. The review shows a promising pipeline aimed at tackling the challenges of today and tomorrow, such as the burden of respiratory tract infections, AMR, the aging of the population, climate change, and zoonotic infections, through leveraging a broad array of new technology platforms. This pipeline is a profound testimony of the commitment of the vaccine industry to ensuring we all benefit from the significant value of vaccination to our society. To download the document, click here.